Recombinant factor VIIa

Recombinant factor VIIa (rFVIIa) which goes by the trade name Novoseven and AryoSeven is a form of blood factor VII.

Medical use
rFVIIa is not, as of 2012, supported by the evidence for most cases of major bleeding. There is a significant risk of arterial thrombosis with its use and thus other than in those with factor VII deficiency should only be given in clinical trails. Recombinant human factor VII while initially looking promising in intracerebral hemorrhage falled to show benefit following further study and this is no longer recommended.

In people with hemophilia type A and B which have deficiency of factor VIII and IX these two factors are administrated for controlling bleeding or as prophylaxis medication before starting surgeries. However after sometimes they develop neutralizing antibodies (NAb) against the drug. These NAbs are increasd during time and cause to inhibit action of medicine (coagulation) in the persons body. The rFVIIa, which is activated form factor VII, is bypassing factor VIII and IX and cause to coagulation of blood without need to factor VIII and IX. This is very important and vital for such patients to shift to proper blood factors according to their level of NAbs. Other indications are including use for patients with acquired hemophilia, people with born deficiency of factor VII, people with Glanzmann's thrombasthenia.

Mechanism of action
This drug is caused activation of extrinsic pathway of blood coagulation.

Manufactur
AryoSeven is a glycoprotein which is produced by recombinant DNA technology and is formulated totally similar to the original drug with the name of Novoseven. The product is actually the first biosimilar or biogeneric of the above mentioned drug with a totally approved similarity. This biomedicine is produced in baby hamster kidney cells (BHK) and has similar characteristics and functions with the native blood factor VII.

Rote of administration
rFVIIa is administrated intravenously(IV) normally under physician supervisory.